Sarepta’s Elevidys Safety Concerns Open Major Opportunity for Solid Biosciences’ (SLDB) SGT-003 in Duchenne Therapy

Solid Biosciences Inc. (NASDAQ:SLDB) is one of the stocks that will double in 2026. On December 4, Needham analyst Gil Blum ...
TipRanks on MSN

REGENXBIO price target raised to $20 from $16 at Leerink

Leerink analyst Mani Foroohar raised the firm’s price target on Regenxbio (RGNX) to $20 from $16 and keeps an Outperform rating on the shares.
Medscape

SMC Approves Givinostat for Duchenne Patients in Scotland

Scotland’s NHS can now offer givinostat to ambulant children with Duchenne muscular dystrophy, marking a step forward in care ...